Related Experiment Video
Updated: Jul 9, 2026
04:30
A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
Published on: May 14, 2013
[Late coronary stent thrombosis and clopidogrel]
I Varvarovský1, J Matejka, A Herman
1Pracoviste invazivní kardiologie Kardio-Troll, Krajská nemocnice Pardubice. ivovarvarovsky@kardio-troll.cz
Vnitrni Lekarstvi
|December 13, 2007
Summary
Late stent thrombosis is a key cardiology concern. Bare metal stents require one month of treatment, while drug-eluting stents need 12 months of clopidogrel for safety.
Area of Science:
- Cardiology
- Interventional Cardiology
Background:
- Late coronary stent thrombosis is a significant clinical issue.
- Understanding its incidence and definition is crucial for patient outcomes.
Purpose of the Study:
- To evaluate the long-term safety of bare metal stents (BMS) and drug-eluting stents (DES).
- To define optimal treatment durations for thienopyridine therapy post-percutaneous coronary intervention (PCI).
Main Methods:
- Review of observational and randomized studies.
- Analysis of safety profiles associated with BMS and DES implantation.
- Assessment of thienopyridine treatment duration based on stent type.
Main Results:
- Bare metal stent implantation is associated with long-term safety after one month of treatment.
- Drug-eluting stent implantation requires a 12-month clopidogrel administration period for optimal safety.
- Incidence and temporal definition of late stent thrombosis are discussed.
Conclusions:
- Treatment duration for thienopyridin therapy varies significantly between BMS and DES.
- Future advancements in DES technology and long-term clopidogrel data may influence current treatment guidelines.
Related Concept Videos
01:28Acute Coronary Syndrome IV: Interprofessional Care
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
01:27Coronary Artery Disease V: Interprofessional Care
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:30Acute Coronary Syndrome I: Introduction
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
01:27Peripheral Artery Disease III: Interprofessional Care
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...